Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Seeks Partners With Pharmas, Hospitals To Make HIV Drugs

This article was originally published in PharmAsia News

Executive Summary

Indian health authorities are requesting public-sector drug makers to manufacture low-cost drugs against HIV. The government has plans to join with major pharmaceutical companies and hospitals to develop other vital drugs at affordable prices. Indian drug makers already have offered to cooperate with the government, but have expressed a desire for a public-private partnership to develop the drugs. The proposed link with the private sector and hospitals would expand the HIV effort to include anti-cancer and other drugs for life-threatening diseases, but which are considered too expensive since they are to be taken over a long term. (Click here for more

You may also be interested in...



India Urges Public-Private Partnerships For State-Owned Pharma Units

FRANKFURT, Germany - Indian Drugs and Pharmaceuticals Ltd., one of India's oldest government-owned units, is shedding its staid image and extending expertise and facilities to other drug companies through potential collaborations or joint ventures. Established in 1961, IDPL was formed with a socialistic outlook of fulfilling medical needs for the poor population in India

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

SynOx Seeks Solution For TGCT With Roche Antibody

The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel